Product Information
ZYLET EYE DROPS is a brand product labeled by Bausch & Lomb Incorporated, priced at $64.5118 per ML under NDC 24208035810. Its NADAC has been published 215 times since Nov 28, 2013.
FDA first approved this application on Dec 14, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 3 mg/mL; mg/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208035810
Classification
Brand
Dosage Form
SUSPENSION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
LOTEPREDNOL ETABONATE; TOBRAMYCINApproval Type
New Drug (NDA)
FDA Application
NDA050804FDA Approved
12/14/2004
TE Code
AB
On Market Since
12/14/2004
Pharmacological Classes
Price Statistics
The NADAC for ZYLET EYE DROPS has been published 215 times since Nov 28, 2013, and over the history we have for it it has risen 114.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $64.5118 per ML |
|---|---|
| All-time high | $64.6564 (Jan 14, 2026) |
| All-time low | $30.1110 (Nov 28, 2013) |
| 52-week high | $64.6564 |
| 52-week low | $64.3943 |
| Median price | $37.9093 |
| Average price | $49.4763 |
| Largest weekly change | +68.1% (Jul 17, 2024) |
| Weeks tracked | 215 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
loteprednol etabonate and tobramycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZYLET EYE DROPS?
The current National Average Drug Acquisition Cost (NADAC) for ZYLET EYE DROPS, manufactured by Bausch & Lomb Incorporated, is $64.5118 per ML (NDC 24208035810), effective Sep 30, 2026.
How has the price of ZYLET EYE DROPS changed over time?
Over the history we have for it, the NADAC for ZYLET EYE DROPS has risen 114.2%. It has been tracked across 215 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ZYLET EYE DROPS?
Since Nov 28, 2013, the NADAC for ZYLET EYE DROPS has ranged from a low of $30.1110 (Nov 28, 2013) to a high of $64.6564 (Jan 14, 2026), with a median of $37.9093 per ML.
Are there cheaper alternatives to ZYLET EYE DROPS?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ZYLET EYE DROPS, is $64.3170 per ML — about 0% below ZYLET EYE DROPS.
Who manufactures ZYLET EYE DROPS?
ZYLET EYE DROPS (NDC 24208035810) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.